Introduction:
Eosinophilic esophagitis (EoE) is an allergic disorder of the esophagus. The histology of EoE is characterized by an eosinophil-predominant infiltrate, but there is also distinctive evidence of esophageal epithelial barrier dysfunction. In EoE, the epithelial architecture shows increased basal layer hyperplasia, dilated intracellular spaces, and epithelial cell dyskeratosis (1). The consequence of this barrier dysfunction is that basal layers of the epithelium and immune cells have contact with both luminal antigens and the esophageal microbiota. Contact with food antigens stimulates secretion of Th2-type cytokines TSLP, IL-25 and IL-33 resulting in recruitment of leukocytes, including eosinophils (2) (3) (4) . Additionally, EoE patients have higher rates of sensitization to esophageal microbes like Candida species (1, 5) . These studies illustrate that epithelial barrier dysfunction plays an important role in permitting antigen exposure and driving inflammation in EoE.
Tight junction (TJ) complexes regulate barrier function within the epithelium. The TJ complex is a dynamic structure comprised of transmembrane claudins, occludin, and cytosolic proteins (i.e.: zonula occludens 1, 2 and 3) which connect the TJ to the cytoskeleton (6) (7) (8) .
Alterations of TJ protein expression have been shown to contribute to epithelial barrier dysfunction, which is of particular consequence in eosinophilic esophagitis (1, 9) . Expression of occludin and claudin1 are decreased in biopsy tissue of EoE patients before and after treatment with swallowed corticosteroid (1). Further exposure to TGF-β1, which is elevated in EoE, diminished in vitro barrier function of immortalized esophageal epithelial cells via specific reduction in expression of the tight-junction molecule, claudin-7 (10) . Additionally, the expression of ZO-1 has been shown to be significantly decreased in the lower esophagus of patients with reflux symptoms nonresponsive to proton pump inhibitor therapy who did not have evidence of EoE, illustrating that esophageal tight junctions are altered in non-EoE associated esophageal pathology (11) .
In other gastrointestinal sites, innate sensing of microbial products by the epithelium has been shown to regulate epithelial barrier function. Signaling via innate immune patternrecognition receptors on epithelial cells has been shown to modulate TJ complex protein expression, thereby modulating epithelial barrier permeability. An increasing body of evidence suggests that Toll-like receptor 2 (TLR2) signaling upregulates TJ proteins ZO-1 and claudin 1in epithelium in the airway, intestine and skin (12) (13) (14) (15) (16) (17) . This mechanism is thought to be one of many host defenses maintaining balance with commensal bacteria. In this study, our aim was to determine if the esophageal epithelium has mechanisms to modulate TJ complex protein expression based upon innate immune sensing via TLR2. In these studies, we utilized the three-dimensional air-liquid interface (ALI) three-dimensional epithelial in vitro culture model.
We hypothesized that TLR2 stimulation would upregulate TJ proteins and may improve esophageal barrier function.
Methods:
Esophageal epithelial cell culture: For this study, we used the immortalized esophageal epithelial cell line (EPC2-hTERT) (18, 19) . We also isolated primary esophageal epithelial cells from three pediatric control patients and three EoE patients as previously described (20) . This was conducted with approval from the Children's Hospital of Philadelphia Institutional Review Board following the US Federal Policy for Protection of Human Subjects. Patients were enrolled in the study following informed consent.
Per diagnostic criteria, all active EoE patients had eosinophil count >15 per high powered field on biopsy. Non-EoE control patients had no anomalies on esophaeal or distal histopathology, no history of immunodeficiency or other identified GI pathology. Cells were grown in keratinocyte serum-free media supplemented with bovine pituitary extract and epidermal growth factor (KSFM, Thermo-Fischer Scientific, USA). Endotoxin-free reagents and media were used for all cell culture and stimulation experiments. 
Quantitative real-time PCR (qRT-PCR):
We harvested RNA using Directzol (Zymo Research, Irvine, CA). DNA was removed by column. We used 0.2 μg of total RNA for reverse-transcription reactions using Advantage RT-for-PCR kit (TakaRa Bio USA). cDNA was used for RT-PCR.
Taqman gene expression assays (Applied Biosystems, human TLR1-10, CLEC7A, CD14), were normalized to the GAPDH internal control signal and custom SYBR green primer assays (listed below) were normalized to β-actin control. Three independent replicates were averaged for the results presented.
Chromatin Immunoprecipitation (ChIP): Five million cells per condition were used to perform
ChIP experiments following the protocol from Upstate Biotechnology (Lake Placid, NY) with some modifications (22) . EPC2-hTERT were harvested from monolayer after 30 minutes of stimulation, treated with 1% formaldehyde for 10 min at room temperature, sonicated and immunoprecipitated overnight at 4 °C. 5 µg of the following antibodies were used: H4ac
(Histone 4 pan-acetyl, Merck Millipore #06-866) anti-H3K27ac (Abcam ab4729), trimethylated H3 lysine 4 (Active Motif 39159), and anti-glutathione-S-transferase (GST) antibody (ThermoFisher 71-7500). Antibody-bound complexes were collected, eluted and extracted as previously described, (22) then RNase treated, and quantitated before analysis by qRT-PCR.
The primers for the ChIP assays are listed below.
Primers for SYBR qRT-PCR:
Primers and probes for ChIP assay: 
Results:
TLR2 and TLR3 were highly expressed in esophageal epithelial cells. We hypothesized that TLRs were involved in regulating epithelial barrier function. To test this hypothesis, we examined expression of PRRs in esophageal epithelial cells from control subjects, subjects with EoE and in the EPC2-hTERT esophageal epithelial cell line ( Figure 1A) . We examined gene expression patterns of TLRs 1-10, CD14 and Dectin 1 (CLEC7A) using qRT-PCR. Both primary esophageal epithelial cells and the EPC2-hTERT cell line express TLR1 through TLR6, with minimal expression of TLR7 through TLR10, CD14 and CLEC7A. TLR2 forms heterodimers with TLR6 and TLR1, both of which were transcribed in the esophageal cells. Both primary and immortalized cell lines expressed TLR2 and TLR3 at the highest levels compared to other PRRs tested. TLR2 protein is expressed on the cell surface, and was detected on epithelial cells using flow cytometry ( Figure 1B & D) . In comparison, the levels of Dectin 1 staining did not exceed isotype control staining ( Figure 1C ). These studies demonstrate that esophageal epithelium expresses a complement of PRR and confirm cell surface expression of TLR2. Improved barrier function following zymosan treatment is TLR2-specific. The full complement of PRR in esophageal epithelium has not been defined and their function are poorly understood.
TLR2 coordinates with TLR6 to recognize zymosan, however zymosan can also be recognized by Dectin-1 as well as other potential epithelial-specific receptors such as Ephrin A2 (23).
Although the EPC2-hTERT have little Dectin 1 expression, we set out to determine if the observed improvement in epithelial barrier function was TLR2-specific. To do so, we coincubated ALI cultures with PAb-hTLR2 and zymosan ( Figure 2D ). PAb-hTLR2 is a polyclonal rat anti-human blocking antibody specific for TLR2 (24, 25) . We observed that the addition of PAb-hTLR2 into the culture media abrogated the increase in epithelial TEER seen following stimulation with zymosan, demonstrating a specific requirement for TLR2 to improve esophageal epithelial barrier function in vitro.
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TLR2 stimulation alters epithelial membrane architecture: We next examined epithelial architectural changes associated with zymosan and peptidoglycan treatment by histological analysis of ALI cultures (Figure 3 ). We observe the expected stratification of the epithelial membrane in unstimulated samples, with thinning of the epithelial membrane following TLR2 agonist treatment (24.8±5.6 μm untreated vs 17.6±6.5 μm zymosan-treated, p<0.001, and 18.7±3.9 peptidoglycan-treated p<0.05). The density of basolateral nuclei was decreased in TLR2 agonist treated cultures ( Figure 3C ). Dilated intracellular spaces are a characteristic finding of epithelial dysfunction in EoE, however, there were no differences amount of dilated intracellular space between treated and untreated cultures ( Figure 3D ). Overall, this corresponds with data obtained in our barrier function assays. Although TLR2 stimulation induces morphologic changes within the epithelium there is no indication of epithelial dilated intracellular spaces which have been demonstrated to correlate with poor barrier function (26, 27) . To test the effect of TLR2 stimulation on TJ complex proteins expression in esophageal epithelial cells, we examined claudin 1 and ZO-1 protein by immunohistochemistry in ALI cultures harvested on day 14 following stimulation with zymosan or peptidoglycan ( Figure 5A ).
Using image analysis to quantitate 3,3'-diaminobenzidine staining intensity, we confirmed that the ZO-1 and claudin 1 staining was significantly higher in zymosan-and peptidoglycan-treated ALI cultures ( Figure 5B and 5C ). We verified increase protein expression of claudin 1 and ZO-1 in ALI following TLR2 stimulation using western blot ( Figure 5D ). From these studies, we conclude that TLR2 stimulation drives increased expression of TJ proteins.
Histone modifications in zymosan-treated epithelial cells. Modification to the chromatin regulatory landscape alters gene expression in response to changes in the cellular environment.
We hypothesized TLR2 stimulation may mediate gene expression changes in tight junction complex proteins within esophageal epithelial cells. These chromatin modifications could be perpetuated across multiple divisions throughout generation of the stratified barrier. We performed chromatin immunoprecipitation (ChIP) assays of EPC2-hTERT cells following stimulation with zymosan ( Figure 6 ) to assess for changes in the chromatin environment at the promoter and enhancer of CLDN1 and TJPN1. Zymosan stimulation increased the acetylation of histone H3K27 and trimethylation of H3K4, though neither reached statistical significance ( Figure 6 ). Acetylation of histone H4 was increased at the CLDN1 enhancer and promoter of zymosan-treated samples. This suggests that Claudin 1 expression was regulated epigenetically by acetylation subsequent to TLR2 stimulation with zymosan.
Discussion:
Our data suggest that recognition of lipoprotein by TLR2 is a specific mechanism that increases epithelial barrier integrity within the esophageal epithelium ( Figure 2 ). Utilizing the airliquid interface model with the esophageal EPC2-hTERT epithelial line, we demonstrate that TLR2 stimulation results in an increase in the expression of TJ-associated proteins claudin 1 and ZO-1 (Figures 4 and 5) . EPC2-hTERT cell lines have been previously characterized, and
share the same morphological characteristics as esophageal basal keratinocytes including key differentiation markers like cytokeratins and the ability to terminally differentiate in vitro in high extracellular calcium media or if cultured to post-confluent state (18, 19, 28) . The esophagus is not a sterile environment, and changes in microbiome composition have been reported in patients with reflux, Barrett's esophagus as well as EoE patients with active inflammation (29) (30) (31) . Further, tissue damage from inflammation or reflux causes release of endogenous damage-associated molecular patterns from necrotic cells which can also interact with esophageal PRR (32, 33) . Therefore, it is plausible that changes in the milieu of PRR-ligands affecting the esophageal epithelium can occur without clinical infection. Our findings describe a mechanism for esophageal barrier modulation in response to these changes.
TJ complex molecules claudin 1 and ZO-1 are upregulated within 24 hours following TLR2 stimulation (Figure 4 ). Our results are consistent with findings from other epithelial types, including intestinal, airway and skin keratinocytes, where TLR2 agonism has been associated with increased expression of TJ complex molecules claudin 1 and ZO-1 (12) (13) (14) (15) 17, 34) . In this study we focused on the response of claudin 1 and ZO-1 because of their critical role in tight junction complex formation. We hypothesize that TLR2 stimulation induces additional alterations in esophageal epithelial cell gene expression that were not captured in our experiments.
Characterizing these additional functional effects will clarify the full impact of TLR2 stimulation on the esophageal mucosa.
Extrapolating upon these findings, we hypothesize that signaling thru innate immune receptors may play a critical role in epithelial cell fate. We find that stimulation of TLR2 with zymosan results in significant enrichment of H4ac at both the CLDN1 promoter and enhancer ( Figure 6 ). H4ac is an activation mark with a widespread distribution at regulatory regions.
TLR2-induced chromatin remodeling could be secondary to an overall shift in the balance of histone acetyltransferases and deacetylate enzymes or more likely due to targeting of chromatin modification complexes to the regulatory regions (35) . Novel therapies with HDAC inhibitors could be investigated to target this pathway within the mucosal for disorders like EoE.
TLRs, including TLR2 and TLR1 are upregulated in the mucosa of patients with EoE and downregulated following treatment with six-food elimination diet (36) . TLR2 single nucleotide polymorphisms (SNP) have been associated with asthma in Puerto Rican, Norwegian, Danish and Caucasian African populations (37) (38) (39) (40) (41) (42) (43) , as well as development of severe atopic dermatitis in Italian and German populations (44, 45) . The mechanism of each SNP is not fully elucidated, however several of the SNPs decrease TLR2 signaling activity (46) . Recent data confirm that EoE is a part of the atopic march, wherein the cumulative risk of EoE increases with each subsequent allergic comorbidity (47) . Further studies elucidating how PRRs such as TLR2
contribute to host barrier responses may help clarify mechanisms of atopic disease including EoE.
In conclusion, we have shown that esophageal epithelial cells express low levels of TLR 
